Methods	Eight-week double-blind, multicentre study.
Participants	In- and outpatients fulfilling DSM-III-R criteria for a major depressive disorder or bipolar disorder. The severity of depression should be 25 or more on the MADRS. Age range: 18-65 years old. pregnancy, lactation, failure to use a safetable contraceptive method, alcohol or drug abuse within the last year, patients with severe somatic, neurologica or psychiatric disease, treatment with MAOI within 2 weeks prior to entry the trial, hypersensitivity to study drugs, suicide risk
Interventions	Fluoxetine: 158 participants. Citalopram: 158 participants. Fluoxetine dose: 20 mg. Citalopram dose range: 20-40 mg/day. Concomitant psychotropic medication was prohibited, but use of benzodiazepines for insomnia
Outcomes	Primary outcome: Montgomery and Asberg Scale for Depression. Secondary outcomes: Hamilton Rating Scale for Depression (HDRS-17), Clinical Global Impression
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear